RMP-A03 Ocular Suspension in Patients With Pterygium (NCT05794204) | Clinical Trial Compass
CompletedPhase 2
RMP-A03 Ocular Suspension in Patients With Pterygium
United States77 participantsStarted 2023-06-09
Plain-language summary
The goal of this clinical trial is to test the safety and efficacy of an ocular medication on the treatment of pterygium.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Must be at least 18 years old
* Diagnosis of pterygium with specified characteristics
* BCVA of 20/200 or better
* Willingness to attend all study visits and comply with the study procedures
Exclusion Criteria:
* Presence of ocular disease
* Double pterygium
* History of ocular surgery
* Presence of ocular trauma
* Use of any ocular medication
* Use of contact lens
* Allergy to any of the components of study drug
* Cannot properly administer study drug
* Clinically significant systemic disease that may place the subject at risk or confound study results
* Participation in an investigational study within 30 days prior to screening
* Female participants who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control (WOCBP).
What they're measuring
1
Change from baseline in pterygium hyperemia grading at Day 28